News

 

Contact Media Relations

Office telephone: +39 0331 581380
mediarelations@nmsgroup.it

NMS Group S.p.A. announced new Board of Directors and Statutory Auditors

NMS Group S.p.A. announced new Board of Directors and Statutory Auditors

Nerviano, 28, May 2024 _NMS Group S.p.A., the largest oncological R&D company in Italy announced, following the shareholder resolution dated 14 May 2024, changes to the Board of Directors and Statutory Auditors of the holding company itself and of all its subsidiaries Nerviano Medical Sciences Srl, Accelera Srl, NerPharMa Srl and SIMIS Srl due to termination of mandates. This transition is part of our ongoing commitment to strong corporate governance and effective leadership.

(Click the title for the complete article)

Dr. Frank Narjes Appointed as Head of Medicinal Chemistry and Drug Design, Elevating Innovation at Nerviano Medical Sciences Srl

Dr. Frank Narjes Appointed as Head of Medicinal Chemistry and Drug Design, Elevating Innovation at Nerviano Medical Sciences Srl

Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., welcomes Dr. Narjes to the esteemed position of Head of Chemistry, heralding a new chapter of pioneering scientific exploration and innovation. With an illustrious career marked by transformational achievements and a relentless pursuit of excellence, Frank brings a wealth of expertise to lead NMS’ chemistry division into unprecedented realms of discovery.

(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. to present data on its platform of payload linkers for ADC conjugation at the World ADC Summit 2024 in London, UK (March 12th-15th, 2024)

Nerviano Medical Sciences S.r.l. to present data on its platform of payload linkers for ADC conjugation at the World ADC Summit 2024 in London, UK (March 12th-15th, 2024)

Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the World ADC 2024 summit that will be held in London, UK (World ADC Europe) from March 12th to March 15th, 2024, with a poster presentation entitled

(Click the title for the complete article)

New European Patent Office study: NMS srl top applicant in Italy during the 2002-2021 period

New European Patent Office study: NMS srl top applicant in Italy during the 2002-2021 period

Nerviano, 1 February 2024     The new study “Patents and Innovation against Cancer”, just released today by the European Patent Office (EPO), reports Italy among top European nations in innovation to fight cancer. In the past 20 years close to 2 000 international patent families (IPFs) have been registered by Italian companies and research facilities. Among them, Nerviano Medical Sciences stands out as the top applicant during the 2002-2021 period.

(Click the title for the complete article)

Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery

Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery

NERVIANO Italy and PARIS France, January 8, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, and Nerviano Medical Sciences S.r.l (NMS), a leading Italian clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, today announced a collaboration agreement in AI for unprecedented kinase project.

(Click the title for the complete article)

 Our Archive

MEDIA RELEASES & NEWS 2020
MEDIA RELEASES & NEWS 2019
MEDIA RELEASES & NEWS 2018
MEDIA RELEASES & NEWS 2020
MEDIA RELEASES & NEWS 2019
MEDIA RELEASES & NEWS 2018

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO